Ranbaxy is in focus again as the US Foods and Drugs Administration (USFDA) has filed an opposition to US-based pharmaceutical firm Mylan Inc's preliminary injunction on the launch of Ranbaxy's cholesterol treatment drug, which is a generic version of Pfizer's Lipitor, reports CNBC-TV18's Ekta Batra quoting sources.
first published: Apr 7, 2011 11:02 am
A collection of the most-viewed Moneycontrol videos.
Nifty Snaps 6-Day Winning Streak As Markets Get In Consolidation Mode| Closing Bell Live
Kenneth Andrade picks three unusual, ignored sectors to bet on in Samvat 2082
Nifty Likely To Consolidate Until It Clears 26,000 Mark Decisively | Opening Bell Live
Nifty Slips Over 150 Points From Day's High But Gains For 6th Day| IT Stocks Surge|Closing Bell Live
